CVRx (NASDAQ:CVRX – Free Report) had its price objective reduced by Cantor Fitzgerald to $2.00 in a report published on Friday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.
A number of other brokerages have also recently commented on CVRX. William Blair cut CVRx from an “outperform” rating to a “market perform” rating in a research report on Friday, November 6th. Craig Hallum cut CVRx from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research report on Friday, August 7th. Lake Street Capital cut their price objective on CVRx from $3.50 to $1.50 and set a “hold” rating for the company in a research note on Friday, November 6th. Piper Sandler lowered shares of CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a report on Friday, August 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research note on Friday, October 30th. One analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $2.70.
Read Our Latest Research Report on CVRx
CVRx Stock Performance
Shares of CVRX stock opened at $0.61 on Friday. The company has a debt-to-equity ratio of 4.24, a current ratio of 6.80 and a quick ratio of 5.71. The company has a market cap of $17.30 million, a price-to-earnings ratio of -0.30 and a beta of 0.81. CVRx has a 1 year low of $0.60 and a 1 year high of $10.28. The firm has a fifty day moving average price of $1.85 and a 200-day moving average price of $5.00.
CVRx (NASDAQ:CVRX – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The company had revenue of $13.83 million during the quarter, compared to the consensus estimate of $13.93 million. CVRx had a negative return on equity of 208.45% and a negative net margin of 88.28%. As a group, equities analysts predict that CVRx will post -2.04 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the stock. Johnson & Johnson purchased a new stake in shares of CVRx during the 2nd quarter worth $20,687,786. Royal Bank of Canada raised its holdings in CVRx by 6,559.3% in the first quarter. Royal Bank of Canada now owns 706,950 shares of the company’s stock worth $6,688,000 after purchasing an additional 696,334 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of CVRx during the second quarter valued at about $6,402,000. FourWorld Capital Management LLC lifted its position in shares of CVRx by 28.9% during the first quarter. FourWorld Capital Management LLC now owns 231,996 shares of the company’s stock valued at $2,195,000 after buying an additional 51,996 shares during the last quarter. Finally, Quantinno Capital Management LP lifted its position in shares of CVRx by 52.4% during the first quarter. Quantinno Capital Management LP now owns 115,818 shares of the company’s stock valued at $1,096,000 after buying an additional 39,845 shares during the last quarter. 75.27% of the stock is owned by institutional investors.
About CVRx
CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.
See Also
- Five stocks we like better than CVRx
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.
